ESTRO 2024 - Abstract Book

S2254

Clinical - Upper GI

ESTRO 2024

Results:

This study included 428 patients, of which 11 patients were treated with post-operative (chemo)-radiotherapy and were excluded from further analyses. 250 patients were treated with neo-adjuvant chemo-radiotherapy and 167 patients with definitive chemo-radiotherapy. Mean age was 67 years (range 41-88); 78% were male and most patients had a performance status of 0 or 1 (92%). 50% were diagnosed with adenocarcinoma, 45% with squamous cell carcinoma, and the remaining with mixed histology. T3-T4 tumors and node-positive disease were found in 86% and 65%, respectively. Treatment characteristics are listed in Table 1.

Variable

Neo-adjuvant RT (n=250)

Definitive RT (n=167)

Gender Male Female

198 52

127 40

Histology Adenocarcinoma Squamous

148 96 6

68 95 4

cell

carcinoma

other

T

stage

37 213

21 146

T1-T2 T3-T4

N

stage

106 144

44 123

N0 N+

Surgery Yes No

231 19

32 123

Chemotherapy Carboplatin/Paclitaxel Cisplatin/5-Fluorouracil Other No

224 24

143 20

2 0

2 2

Target

volumes

(cm3,

mean)

44.0 5.8

50.5 8.3

GTV

T

GTV N

Total

dose

(Gy)

193 23 10 0

0 0 164 3

41.4 45 50/50.4 60+

Dosimetrics

(Gy,

mean)

7.95 14.67

12.6 8.96

Mean

Lung

dose